Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Juxtapid
Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor indicated as an adjunct to a low-fat diet and other lipid-lowering treatments (e.g., statins, bile acid sequestrants) in patients with homozygous familial hypercholesterolemia (HoFH), a rare, inherited disorder characterized by severely elevated low-density lipoprotein cholesterol (LDL-C) levels. Lomitapide reduces the production of very-low-density lipoprotein (VLDL) in the liver, thereby decreasing LDL-C and other atherogenic lipoproteins.
For the treatment of homozygous familial hypercholesterolemia (HoFH) as an adjunct to diet and other lipid-lowering therapies.
Lomitapide can cause liver toxicity, including steatohepatitis, fibrosis, cirrhosis, and liver failure. Patients must undergo liver function tests before starting treatment and regularly thereafter. Lomitapide can also increase liver fat content, which can exacerbate pre-existing liver conditions. Concomitant use with other hepatotoxic medications should be avoided where possible.
Outcome:
Increased lomitapide plasma concentrations
Mechanism:
Inhibition of CYP3A4
Outcome:
Decreased lomitapide absorption
Mechanism:
Binding to bile acid sequestrants
Outcome:
No clinically significant interaction expected
Mechanism:
Not applicable
Most likely new formulation: extended-release version (Year: 2026, 70% confidence)
Based on current usage and safety profile, the likelihood of continued FDA approval remains high (95% confidence).
Microsomal Triglyceride Transfer Protein (MTP) Inhibitor
Azetidinone